Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tissue Regenix Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.34.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Tissue Regenix Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Tissue Regenix Group's Cash-to-Debt or its related term are showing as below:
FRA:LSW'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: 1.01 Max: No Debt
Current: 0.34
During the past 13 years, Tissue Regenix Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.18. And the median was 1.01.
FRA:LSW's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.575
vs FRA:LSW: 0.34
Tissue Regenix Group (FRA:LSW) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Tissue Regenix Group Cash-to-Debt Related Terms
Tissue Regenix Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:LSW vs VRTX, REGN, ALNY: Cash-to-Debt Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Cash-to-Debt of 0.34 as of Dec. 2025. This is 66% below median its historical median of 1.01. Over the past decade, Tissue Regenix Group's Cash-to-Debt has ranged from 0.18 to 10,000.00.
Is Tissue Regenix Group's Cash-to-Debt too high?
Tissue Regenix Group's current Cash-to-Debt of 0.34 is 66% below median its 10-year median of 1.01. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. Tissue Regenix Group's value of 0.34 is 94.8% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Cash-to-Debt compare to VRTX and REGN?
Tissue Regenix Group's Cash-to-Debt of 0.34 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.58. Tissue Regenix Group's value of 0.34 is 94.8% below this benchmark. Historically, Tissue Regenix Group's own Cash-to-Debt has ranged from 0.18 to 10,000.00 over the past decade. While the company's 10-year median is 1.01 vs. the industry median of 6.58, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Cash-to-Debt of 0.34 is 94.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Cash-to-Debt is 0.34, which is 66% below median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Cash-to-Debt of 0.34. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Cash-to-Debt is 0.34, which is 66% below median its 10-year median of 1.01 and 94.8% below the Biotechnology industry median of 6.58. Tissue Regenix Group's overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Cash-to-Debt is 0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Cash-to-Debt: 0.34 (66% below median its 10-year median of 1.01)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 94.8% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
